Mammoth Biosciences

Mammoth Biosciences is a biotechnology company based in Brisbane, California[1] developing diagnostic tests using CRISPR-Cas12a and CRISPR-based therapies using its proprietary ultra-small CRISPR systems. The company was founded in 2017[2] by Jennifer Doudna, Janice Chen, and Lucas Harrington of the University of California, Berkeley, and Trevor Martin of Stanford University.[3]

Mammoth signed agreements in December 2019 and January 2020 with Horizon Discovery to combine Mammoth's intellectual property in CRISPR with Horizon's expertise in Chinese hamster ovary cells.[4] Also in 2020, both Mammoth Biosciences and Sherlock Biosciences from the Broad Institute used their similar CRISPR technologies to develop tests for COVID-19.[5] The technology, which is owned under the trademark of DETECTR BOOST, has been contracted to be manufactured by Merck & Co.[6] In 2023, the company announced that it will focus on developing CRISPR-based therapies.[7] Mammoth previously announced partnerships with Vertex Pharmaceuticals (2021) and Bayer (2022) to research ultra-small CRISPR systems for in vivo editing.[8][9]

See also

References
  1. Fannin, Rebecca (2022-03-12). "The 30-year-old female founder at the forefront of a billion-dollar bet on CRISPR gene editing". CNBC. Retrieved 2023-08-14.
  2. "Mammoth Biosciences". Craft.co. Archived from the original on 2021-05-27. Retrieved 2021-05-27.
  3. Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 422–423. ISBN 978-1-9821-1585-2.
  4. "Horizon Discovery, Mammoth Biosciences Sign Second CRISPR Tools Development Agreement". Genomeweb. 2020-01-13. Retrieved 2021-05-27.
  5. Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 427–433. ISBN 978-1-9821-1585-2.
  6. Mcardle, Matthew (May 17, 2021), Increasing SARS-CoV-2 testing capacity with CRISPR-based rapid testing, SelectScience, retrieved September 9, 2021{{citation}}: CS1 maint: date and year (link)
  7. "CRISPR unicorn Mammoth backs off diagnostics research, laying off 35 on testing team to focus on therapeutics". Endpoints News. Retrieved 2023-09-19.
  8. Hart, Robert. "Mammoth Biosciences Inks $691 Million Deal With Vertex For Crispr Gene-Editing Therapies". Forbes. Retrieved 2023-09-19.
  9. Burger, Ludwig; Weiss, Patricia (2022-01-10). "Bayer in gene therapy collaboration with Mammoth Biosciences". Reuters. Retrieved 2023-09-19.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.